My CPNP

My CPNP provides quick access to the most important features on cpnp.org.

You will see your important notices, and you will have direct access to your exams and other action items.

Log in now to see your personalized page.

User login

Industry News

Vincenzi B, Stock S, Borba CPC, et al. A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism. schizophr Res 2014;159(2-3):395-403. doi:10.1016/j.schres.2014.08.021.
OBJECTIVE: The aim of this study was to investigate the role of pravastatin, as an adjunctive therapy, on inflammatory markers, lipid and glucose metabolism, psychopathology, and cognition in subjects with schizophrenia and schizoaffective disorder. METHODS: Schizophrenia or schizoaffective subjects (N=60) were randomized to receive either a 12-week supply of pravastatin 40 mg/day or placebo treatment. Anthropometric measures, lipids and glucose metabolism, inflammatory markers, psychopathology and...
Romero-Pimentel AL, Vázquez-Roque RA, Camacho-Abrego I, et al. Histological correlates of N40 auditory evoked potentials in adult rats after neonatal ventral hippocampal lesion: animal model of schizophrenia. schizophr Res 2014;159(2-3):450-7. doi:10.1016/j.schres.2014.09.009.
The neonatal ventral hippocampal lesion (NVHL) is an established neurodevelopmental rat model of schizophrenia. Rats with NVHL exhibit several behavioral, molecular and physiological abnormalities that are similar to those found in schizophrenics. Schizophrenia is a severe psychiatric illness characterized by profound disturbances of mental functions including neurophysiological deficits in brain information processing. These deficits can be assessed by auditory evoked potentials (AEPs), where...

CPNP News

CPNP Joins PCSS-O and PCSS-MAT Steering Committees

To better prepare pharmacists and other providers to meet the rising demand for services and solutions regarding opioid use disorders and treatment, CPNP recently joined the steering committees of PCSS-O and PCSS-MAT (Provider’s Clinical Support System for Opioid Therapies and Medication Assisted Therapies, respectively).

CPNP Announces 2015 Research Award Finalists

A record number 195 abstracts will be featured at the CPNP Annual Meeting. Posters will be displayed Monday, April 20, 2015 between 8:00 a.m. and 7:15 p.m. Students, residents, and fellows will man their posters for a 1 hour segment in the morning while all other posters and award posters will be manned during a 1 hour evening event. Conversations and networking can continued during the reception that concludes Monday evening. A special thank you to the abstract reviewers who participated in making these selections.

CPNP Releases Position Paper on Psychiatric Pharmacists as an Essential Member of Every Healthcare Team

The College of Psychiatric & Neurologic Pharmacists (CPNP) has developed an official position paper to help increase patient access to comprehensive medication management and to support efforts to obtain payment for the service.

College of Psychiatric and Neurologic Pharmacists Announces Election of 2015-2017 Officers

The College of Psychiatric and Neurologic Pharmacists (CPNP) membership has elected three officers to serve on the 2015-2017 Board of Directors. Assuming their offices effective July 1, 2015, will be Drs. Sara Dugan, Robert Haight, and Christopher Thomas.

Newly elected Board members will fill the following roles on the Board:

College of Psychiatric and Neurologic Pharmacists Announces Slate for 2015-2017 Board Officer Election

The College of Psychiatric and Neurologic Pharmacists (CPNP) Nominations Committee is pleased to announce the consideration of over 25 individuals for 3 positions on the 2015-2017 CPNP Board of Directors. Now narrowed to a slate of 6 candidates, CPNP active members will have the opportunity to select 1 individual to serve in each position. Elections will take place online at cpnp.org from November 3-21, 2014. A link to the voting center will be sent via email to all active members on November 3.

Candidates Include:

President-Elect Candidates:

The College of Psychiatric and Neurologic Pharmacists (CPNP) Announces the Recipient of the 2015 Judith J. Saklad Memorial Award

The College of Psychiatric and Neurologic Pharmacists (CPNP) is pleased to announce the recipient of the 2015 Judith J. Saklad Memorial Award, Carla Cobb, PharmD, BCPP. Dr. Cobb is a Psychiatric Pharmacist at RiverStone Health Clinic in Billings, Montana.

CPNP Generates Buzz at the NAMI Annual Meeting

The National Alliance on Mental Illness (NAMI) held their national convention in Washington, D.C., September 3-6. The popular CPNP “Ask the Psychiatric Pharmacist” booth received special mention in NAMI’s post-convention video update from Mary Giliberti, NAMI Executive Director.

In the recorded interview (timestamp 2:25-3:25), CPNP member Judy Curtis explains who CPNP is and what neuropsychiatric pharmacists contribute to patient care. CPNP student members Kayla Tegeler and Marcus Ellis, with assistance from Heidi Wehring, PharmD, BCPP, staffed the “Ask the Psychiatric Pharmacist” booth and shared the type of questions they answered at the very popular booth.

CPNP has had a long-lasting relationship with NAMI staffing the Ask the Psycyhiatric Pharmacist booth and providing 2 educational sessions (Medication and Treatment Challenges for the Young Adults and New Psychiatric Medications: Knowledge is Power) as a way to reinforce the important role psychiatric pharmacists can bring to the treatment team. A special thanks to all of the volunteers who represented CPNP and provided valuable services at NAMI 2014: Shelly Spollen, Karen Moeller, Judy Curtis, LaGenia Bailey, Alice Mascialino, Heidi Wehring, Kayla Tegeler, Marcus Ellis, Jerry Overman, and Cassidy Zammit.

If you have any questions, please contact us.